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Ergotism associated with HIV antiviral protease
inhibitor therapy
Zachary K. Baldwin, MD, and Chris C. Ceraldi, MD, Oakland, Calif
Ergotism is a rare condition of acute vasospasm found classically in young and middle-aged women taking ergot alkaloid
agents to treat migraine headache. We report the case of a young man with human immunodeficiency virus (HIV)
positivity and describe the drug interaction between protease inhibitors and ergot alkaloid agents, which most likely
predisposed to development of ergot toxicity. The HIV-positive population receiving antiviral therapy may be an
underrecognized group at risk for ergotism through decreased hepatic metabolism of ergot preparations. (J Vasc Surg
2003;37:676-8.)
Ergot alkaloid agents exert their effect by direct vaso-
constriction, central sympatholysis, and peripheral -ad-
renergic blockade.1 They are hepatically metabolized by a
subgroup of the cytochrome P-450 isoenzymes CYP3A4.2
Compounds also metabolized via this enzyme pathway,
including erythromycin, theophylline, carbamazapine, and
cyclosporine, can alter ergot metabolism, resulting in drug
concentration levels greater than normal.3
Protease inhibitors such as ritonavir and indinivir, used
for their antiviral properties in patients positive for human
immunodeficiency virus (HIV), are also metabolized
through the cytochrome P-450 pathway and are potent
inhibitors of the CYP3A4 isoenzyme.4 Although reported
in the medical literature,5-13 the association between ergot-
ism and protease inhibitors has yet to be reported in the
vascular literature. We report the case of a 31-year-old
HIV-positive man receiving antiviral therapy in whom
manifestations of ergotism developed after he was given
ergotamine tartrate (Cafergot; Sandoz Pharmaceuticals,
East Hanover, NJ ) for treatment of migraine headache.
CASE REPORT
A 36-year-old man with a history of HIV and lymphoma had
a 1-week history of progressive bilateral claudication and forefoot
cyanosis. HIV had been diagnosed 8 years before, and the patient
was receiving triple antiviral therapy with two protease inhibitors
and a nucleoside analog. He had undergone exploratory laparot-
omy 4 months previously for resection of a small bowel lymphoma.
Postoperatively he received chemotherapy with CHOP (cyclo-
phosphamide, hydroxydaunomycin, vincristine sulfate [Oncovin],
and prednisone). Deep venous thrombosis also developed, which
was treated with anticoagulation therapy with coumadin. A Green-
field filter was subsequently placed because of pulmonary embolus.
The patient had never smoked and had no history of diabetes,
hypertension, hyperlipidemia, or other risk factors for atheroscle-
rosis. He had a history of migraine headache, had used ergot
preparations in the past, and had taken a single 2 mg dose of
ergotamine tartrate on the day before onset of symptoms.
Symptoms were more severe on the left. He described pares-
thesia and coolness of the feet, but no pain. Physical examination
revealed palpable femoral pulses bilaterally but no palpable pulses
below the groin. The left foot was cyanotic and cool, with mildly
decreased sensation. Motor function was normal bilaterally. Dopp-
ler ultrasound scans demonstrated no signals in the left foot and a
biphasic posterior tibial artery signal in the right. Capillary refill was
present but delayed.
Arteriograms showed diffuse spasm of the tibial arteries con-
sistent with ergot toxicity (Figure). The patient was admitted to
the hospital and given heparin intravenously and nifedipine orally.
The next day the symptoms were markedly improved, with reso-
lution of cyanosis and warm feet bilaterally. Palpable pulses were
present in the right foot. Doppler ultrasound scans showed bipha-
sic signals in the left foot, although pulses were not palpable. The
patient was discharged that day with oral nifedipine therapy and
instructions to avoid all ergot-containing substances and caffeine.
At 1-week follow-up all symptoms had resolved and pedal pulses
were palpable bilaterally. Nifedipine was discontinued.
DISCUSSION
Ergotism is well described.14 Symptoms of toxicity
include not only manifestations of peripheral vasospasm
and thrombosis but also neurologic side effects (headache,
psychosis) and alimentary symptoms (nausea, cramping,
diarrhea). Arteriograms reveal generalized vasospasm, for-
mation of collateral vessels, and, in some cases, thrombo-
sis.1 Although most ergot toxicity is associated with exces-
sive dosing, ergotism has been reported after extremely
small doses and in patients who have been regular users at
the recommended dosage.15,16 Furthermore, erratic gas-
trointestinal absorption of ergot compounds and poor cor-
relation of toxic symptoms to ergot blood levels make
symptom severity and duration difficult to predict based on
dosage consumed.17
The question posed by this case and addressed to some
extent in the medical literature5-13 is whether the incidence
of ergotism is increased in patients taking protease inhibi-
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tors, as a result of inhibition of the primary means of ergot
metabolism, ie, the CYP3A4 isoenzyme pathway. Other
commonly used medications that compete with this path-
way (Table) have been associated with ergotism.18-20 Al-
though the occurrence of ergotism can be idiosyncratic, it is
presumed that incidence increases with elevated peak serum
levels.21 Hence, especially concerning drug-drug interac-
tions and altered ergot metabolism, symptoms of toxicity
may develop in the context of a relatively small dose of
ergotamine or its derivatives.
Since the introduction in 1994 of protease inhibitors
for antiviral therapy there have been nine reports of ergot-
protease inhibitor interaction associated with ergotism.5-13
Of the nine cases presented, five patients were male, and
eight were 40 years of age or younger. All were HIV-
positive, and eight of the nine had ischemia of the lower or
upper extremity or both. All nine patients had taken only
prescribed doses of ergotamine, and three patients had
taken only a single 1 or 2 mg dose. This suggests higher
than normal peak serum levels of ergotamine caused by
potent inhibition of ergotamine metabolism by protease
inhibitors. Furthermore, new recommendations for antivi-
ral regimens containing two protease inhibitors may poten-
tiate this inhibition even more.
A, B, C, Arteriograms of the left lower extremity demonstrate diffuse spasm, primarily of the tibial arteries.
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The ideal treatment of ergotism has yet to be defined;
multiple successful methods have been reported. Treat-
ment alternatives include calcium channel blockers; hepa-
rin; oral prazocin hydrochloride, an -adrenergic blocker;
catheter-based intra-arterial or systemic vasodilator therapy
with nitroprusside, prostacyclin, or prostaglandin E2; and
intra-arterial balloon dilation.1,17 Each of these agents and
a combination of multiple agents have been used success-
fully.1,5-13 In this case, orally administered calcium channel
blockers and heparin, and discontinuance of caffeine and
the ergot preparation were sufficient. Although neither
could be considered first-line therapy in all cases of ergot
toxicity, this regimen appears reasonable for mild cases in
which limb threat is not imminent.
In summary, potent inhibition of ergot metabolism by
protease inhibitors predisposes to ergot toxicity even at
prescribed doses. The incidence of ergotism may be in-
creased among HIV-positive patients taking antiviral pro-
tease inhibitors. Vascular surgeons should include ergotism
in the differential diagnosis in any young HIV-positive
patient with ischemia of the extremities.
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Inhibitors of cytochrome P-450 isoenzyme CYP-3A4
Macrolide antibiotics Azole antifungal agents
Erythromycin Intraconazole
Clarithromycin Ketoconazole
Azithromycin
Protease inhibitors Other
Ritonavir Cyclosporin
Indinavir Diltiazem
Amprenavir Nefazodone
Nelfinavir Grapefruit juice
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